KEGG   PATHWAY: oaa05212Help
Entry
oaa05212                    Pathway                                

Name
Pancreatic cancer - Ornithorhynchus anatinus (platypus)
Description
Infiltrating ductal adenocarcinoma is the most common malignancy of the pancreas. When most investigators use the term 'pancreatic cancer' they are referring to pancreatic ductal adenocarcinoma (PDA). Normal duct epithelium progresses to infiltrating cancer through a series of histologically defined precursors (PanINs). The overexpression of HER-2/neu and activating point mutations in the K-ras gene occur early, inactivation of the p16 gene at an intermediate stage, and the inactivation of p53, SMAD4, and BRCA2 occur relatively late. Activated K-ras engages multiple effector pathways.  Although EGF receptors are conventionally regarded as upstream activators of RAS proteins, they can also act as RAS signal transducers via RAS-induced autocrine activation of the EGFR family ligands. Moreover, PDA shows extensive genomic instability and aneuploidy. Telomere attrition and mutations in p53 and BRCA2 are likely to contribute to these phenotypes. Inactivation of the SMAD4 tumour suppressor gene leads to loss of the inhibitory influence of the transforming growth factor-beta signalling pathway.
Class
Human Diseases; Cancers
BRITE hierarchy
Pathway map
Pancreatic cancer
oaa05212

All organismsOrtholog table
Organism
Ornithorhynchus anatinus (platypus) [GN:oaa]
Gene
GTPase KRas-like; K07827 GTPase KRas [KO:K07827]
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta [KO:K00922] [EC:2.7.1.153]
phosphatidylinositol-4; K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase [EC:2.7.1.153] [KO:K00922] [EC:2.7.1.153]
phosphatidylinositol-4; K00922 phosphatidylinositol-4,5-bisphosphate 3-kinase [EC:2.7.1.153] [KO:K00922] [EC:2.7.1.153]
phosphoinositide 3-kinase regulatory subunit 5-like; K02649 phosphoinositide-3-kinase, regulatory subunit [KO:K02649]
PIK3R2; phosphoinositide-3-kinase, regulatory subunit 2 (beta) [KO:K02649]
phosphatidylinositol 3-kinase regulatory subunit alpha-like; K02649 phosphoinositide-3-kinase, regulatory subunit [KO:K02649]
phosphatidylinositol 3-kinase regulatory subunit gamma-like; K02649 phosphoinositide-3-kinase, regulatory subunit [KO:K02649]
ARHGEF6; Rac/Cdc42 guanine nucleotide exchange factor (GEF) 6 [KO:K05729]
ras-related C3 botulinum toxin substrate 1-like; K04392 Ras-related C3 botulinum toxin substrate 1 [KO:K04392]
ras-related C3 botulinum toxin substrate 2-like; K07860 Ras-related C3 botulinum toxin substrate 2 [KO:K07860]
nuclear factor NF-kappa-B p105 subunit-like; K02580 nuclear factor NF-kappa-B p105 subunit [KO:K02580]
nuclear factor NF-kappa-B p105 subunit-like; K02580 nuclear factor NF-kappa-B p105 subunit [KO:K02580]
transcription factor p65-like; K04735 transcription factor p65 [KO:K04735]
RAC-gamma serine/threonine-protein kinase-like; K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] [KO:K04456] [EC:2.7.11.1]
RAC-alpha serine/threonine-protein kinase-like; K04456 RAC serine/threonine-protein kinase [EC:2.7.11.1] [KO:K04456] [EC:2.7.11.1]
CHUK; conserved helix-loop-helix ubiquitous kinase [KO:K04467] [EC:2.7.11.10]
IKBKB; inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta [KO:K07209] [EC:2.7.11.10]
NF-kappa-B essential modulator-like; K07210 inhibitor of nuclear factor kappa-B kinase subunit gamma [KO:K07210]
caspase-9-like; K04399 caspase 9 [EC:3.4.22.62] [KO:K04399] [EC:3.4.22.62]
serine/threonine-protein kinase A-Raf-like; K08845 A-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1] [KO:K08845] [EC:2.7.11.1]
serine/threonine-protein kinase B-raf-like; K04365 B-Raf proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1] [KO:K04365] [EC:2.7.11.1]
RAF proto-oncogene serine/threonine-protein kinase-like; K04366 RAF proto-oncogene serine/threonine-protein kinase [EC:2.7.11.1] [KO:K04366] [EC:2.7.11.1]
dual specificity mitogen-activated protein kinase kinase 1-like; K04368 mitogen-activated protein kinase kinase 1 [EC:2.7.12.2] [KO:K04368] [EC:2.7.12.2]
mitogen-activated protein kinase 1-like; K04371 extracellular signal-regulated kinase 1/2 [EC:2.7.11.24] [KO:K04371] [EC:2.7.11.24]
MAPK9; mitogen-activated protein kinase 9 [KO:K04440] [EC:2.7.11.24]
MAPK8; mitogen-activated protein kinase 8 [KO:K04440] [EC:2.7.11.24]
uncharacterized LOC100082590; K04440 c-Jun N-terminal kinase [EC:2.7.11.24] [KO:K04440] [EC:2.7.11.24]
ral guanine nucleotide dissociation stimulator-like; K08732 ral guanine nucleotide dissociation stimulator [KO:K08732]
ras-related protein Ral-A-like; K07834 Ras-related protein Ral-A [KO:K07834]
ras-related protein ralB-B-like; K07835 Ras-related protein Ral-B [KO:K07835]
RALBP1; ralA binding protein 1 [KO:K08773]
cell division control protein 42 homolog; K04393 cell division control protein 42 [KO:K04393]
protransforming growth factor alpha-like; K08774 transforming growth factor, alpha [KO:K08774]
EGFR; epidermal growth factor receptor [KO:K04361] [EC:2.7.10.1]
signal transducer and activator of transcription 1-like; K11220 signal transducer and activator of transcription 1 [KO:K11220]
vascular endothelial growth factor A-like; K05448 vascular endothelial growth factor A [KO:K05448]
cyclin-dependent kinase inhibitor 2A; K06621 cyclin-dependent kinase inhibitor 2A [KO:K06621]
cyclin-dependent kinase 6-like; K02091 cyclin-dependent kinase 6 [EC:2.7.11.22] [KO:K02091] [EC:2.7.11.22]
G1/S-specific cyclin-D1-like; K04503 cyclin D1 [KO:K04503]
RB1; retinoblastoma 1 [KO:K06618]
transcription factor E2F3-like; K06620 E2F transcription factor 1/3 [KO:K06620]
transcription factor E2F2-like; K09389 E2F transcription factor 2 [KO:K09389]
transforming growth factor beta-2-like; K13376 transforming growth factor beta-2 [KO:K13376]
transforming growth factor beta-3-like; K13377 transforming growth factor beta-3 [KO:K13377]
TGF-beta receptor type-1-like; K04674 TGF-beta receptor type-1 [EC:2.7.11.30] [KO:K04674] [EC:2.7.11.30]
TGFBR2; transforming growth factor, beta receptor II (70/80kDa) [KO:K04388] [EC:2.7.11.30]
SMAD2; SMAD family member 2 [KO:K04500]
mothers against decapentaplegic homolog 4-like; K04501 mothers against decapentaplegic homolog 4 [KO:K04501]
BRCA2; breast cancer 2, early onset [KO:K08775]
DNA repair protein RAD51 homolog 1-like; K04482 DNA repair protein RAD51 [KO:K04482]
DNA repair protein RAD51 homolog 1-like; K04482 DNA repair protein RAD51 [KO:K04482]
Compound
C00416  
Phosphatidate
C05981  
Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Von Hoff DD, Evans DB, Hruban RH (ed).
  Title
Pancreatic Cancer
  Journal
Jones and bartlett publishers (2005)
Reference
(Japanese)
  Authors
Niitsu Y, Yokota J (ed).
  Title
[Oncogenes and Tumor Suppressor Genes for Medical Oncologist] (In Japanese)
  Journal
Nankodo (1999)
Reference
  Authors
Bardeesy N, DePinho RA.
  Title
Pancreatic cancer biology and genetics.
  Journal
Nat Rev Cancer 2:897-909 (2002)
Reference
  Authors
Bardeesy N, Sharpless NE, DePinho RA, Merlino G.
  Title
The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model.
  Journal
Semin Cancer Biol 11:201-18 (2001)
Reference
  Authors
Cowgill SM, Muscarella P.
  Title
The genetics of pancreatic cancer.
  Journal
Am J Surg 186:279-86 (2003)
Reference
  Authors
Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA.
  Title
Genetics and biology of pancreatic ductal adenocarcinoma.
  Journal
Genes Dev 20:1218-49 (2006)
Reference
  Authors
Shields JM, Pruitt K, McFall A, Shaub A, Der CJ.
  Title
Understanding Ras: 'it ain't over 'til it's over'.
  Journal
Trends Cell Biol 10:147-54 (2000)
Reference
  Authors
Holbro T, Civenni G, Hynes NE.
  Title
The ErbB receptors and their role in cancer progression.
  Journal
Exp Cell Res 284:99-110 (2003)
Reference
  Authors
Marmor MD, Skaria KB, Yarden Y.
  Title
Signal transduction and oncogenesis by ErbB/HER receptors.
  Journal
Int J Radiat Oncol Biol Phys 58:903-13 (2004)
Reference
  Authors
DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW.
  Title
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.
  Journal
Oncogene 22:7781-95 (2003)
Reference
  Authors
Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC, Peng Z, Huang S, Xiong HQ, Abbruzzese JL, Xie K.
  Title
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis.
  Journal
Oncogene 22:319-29 (2003)
Reference
  Authors
Toyonaga T, Nakano K, Nagano M, Zhao G, Yamaguchi K, Kuroki S, Eguchi T, Chijiiwa K, Tsuneyoshi M, Tanaka M.
  Title
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
  Journal
Cancer Lett 201:107-16 (2003)
Reference
  Authors
Schmid RM.
  Title
Genetic basis of pancreatic cancer.
  Journal
Best Pract Res Clin Gastroenterol 16:421-33 (2002)
Reference
  Authors
Elliott RL, Blobe GC.
  Title
Role of transforming growth factor Beta in human cancer.
  Journal
J Clin Oncol 23:2078-93 (2005)
Reference
  Authors
Rudkin TM, Foulkes WD.
  Title
BRCA2: breaks, mistakes and failed separations.
  Journal
Trends Mol Med 11:145-8 (2005)
Reference
  Authors
Venkitaraman AR.
  Title
Functions of BRCA1 and BRCA2 in the biological response to DNA damage.
  Journal
J Cell Sci 114:3591-8 (2001)
KO pathway
 

DBGET integrated database retrieval system